Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. develops targeted cancer therapies as a clinical-stage biopharmaceutical company, with news centered on antibody-drug conjugate programs and related financial updates. Its principal update themes include SIM0505, a Cadherin-6-directed ADC with a topoisomerase 1 inhibitor payload, and LNCB74, a B7-H4-directed ADC.
Company announcements also cover clinical data presentations, FDA interactions such as Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, collaborations with Simcere Zaiming, business updates, financial results, and participation in healthcare investor conferences.
NextCure (Nasdaq: NXTC) and privately held Avere Therapeutics agreed to an all-stock merger that will combine NextCure’s public listing with Avere’s oral IL‑23 program, AVR‑001. The deal is expected to close in the second half of 2026, after which the combined company will operate as Avere Therapeutics and trade on Nasdaq under the ticker “AVRX”.
A concurrent $320 million private placement, including $251 million of convertible notes exchanged into common stock, is expected to fund operations through a global Phase 2b psoriasis readout, and the starts of Phase 3 psoriasis and Phase 2b ulcerative colitis trials. Avere holds ex‑China rights to AVR‑001 under a license from Hansoh, which will receive $120 million in upfront payments, up to $2.18 billion in milestones, and mid‑single to low‑double digit royalties.
NextCure (Nasdaq:NXTC) announced that a replay of its virtual key opinion leader (KOL) event on SIM0505 is now available. The event followed ASCO 2026 dose escalation data from the Phase 1 trial in ovarian cancer and uterine serous carcinoma.
Experts discussed first reported clinical efficacy data for these difficult-to-treat gynecologic cancers.
NextCure (Nasdaq:NXTC) and partner Simcere Zaiming reported positive Phase 1 dose escalation data for SIM0505, an anti-CDH6 ADC, in advanced gynecologic cancers at ASCO 2026.
Among therapeutic-dose patients (4.8–8.0 mg/kg) with ≥12 weeks follow-up, ORR was 55% in gynecologic cancers, 52.9% in ovarian and 66.7% in USC, with favorable overall safety in 59 heavily pretreated patients. A virtual KOL event is scheduled for June 2, 2026 at 8:00 AM ET.
NextCure (Nasdaq: NXTC) reported Q1 2026 results and a business update on May 7, 2026. Key clinical progress: FDA Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, Phase 1 dose-escalation data to be presented at ASCO 2026 on June 1, 2026, and initiation of a dose-optimization study. Cash totaled $29.7M at March 31, 2026, with runway expected into the first half of 2027 through SIM0505 proof-of-concept.
NextCure (Nasdaq: NXTC) and Simcere Zaiming initiated the dose optimization portion of the Phase 1 study of SIM0505, an investigational CDH6-targeting ADC, focused initially on patients with platinum-resistant ovarian cancer (PROC).
The program will expand U.S. and China trial sites and add sites in Canada and Europe. Phase 1 data readout is planned for ASCO 2026.
NextCure (Nasdaq: NXTC) and Simcere will present Phase 1 data for SIM0505, an anti-CDH6 antibody-drug-conjugate (ADC), as a poster at ASCO 2026.
The poster (Abstract #5580, Board 246) will be presented June 1, 2026, by Xiaohua Wu, MD, PhD; the poster will be posted on the company investor site after the session.
NextCure (Nasdaq: NXTC) announced the FDA granted Fast Track designation to SIM0505, an anti-CDH6 antibody-drug conjugate, for treatment of platinum-resistant ovarian cancer.
The company plans to begin dose optimization in Q2 2026 and will present Phase 1 data at ASCO 2026, enabling closer FDA engagement to accelerate development.
NextCure (Nasdaq: NXTC) and Simcere announced that an abstract for SIM0505 (CDH6 ADC) was accepted for presentation at ASCO 2026, held May 29–June 2 in Chicago. SIM0505 is an investigational ADC targeting Cadherin-6 (CDH6) with a proprietary TOPOi payload.
The ongoing open-label Phase 1 study (NCT06792552) is evaluating SIM0505 in advanced solid tumors, including ovarian cancer, with emphasis on platinum-resistant ovarian cancer.
NextCure (Nasdaq: NXTC) provided a business update and reported full-year 2025 results on March 5, 2026. Key clinical milestones include SIM0505 Phase 1 dose escalation data expected Q2 2026 and initiation of a Phase 1 dose optimization study in platinum resistant ovarian cancer in Q2 2026. LNCB74 enrollment continues with a trial update planned H2 2026. Financials: $41.8M cash at year-end and net loss of $55.8M for 2025; company expects runway into H1 2027 through SIM0505 proof-of-concept.
NextCure (NASDAQ: NXTC) provided a business update on Jan 23, 2026, reporting clinical progress for two ADC programs and a preliminary year-end cash position.
SIM0505 (CDH6 ADC): Phase 1 dose-escalation data from U.S. and China cohorts are expected in Q2 2026; company is adding sites and increasing drug supply to start dose optimization in H1 2026. LNCB74 (B7-H4 ADC): dose escalation expanded into higher cohorts with prioritization of high B7-H4 breast and gynecological cancer patients; proof-of-concept timing delayed to a trial update in 2H 2026. Financials: preliminary cash and equivalents approx $41.8M, expected to fund operations into 1H 2027.